Insud Pharma
Roberto Heras Alberruche serves as the Analytical Development Manager for R&D Injectables at Insud Pharma since September 2018, overseeing analytical development for various injectable projects, including method validation and stability studies. Previously, Roberto held the position of Analytical Development Team Leader at Chemo from September 2016 to August 2018, where responsibilities included establishing a new R&D laboratory for injectables and managing analytical development projects. With a career spanning from September 1996 to August 2016 at Laboratorios Alcala Farma, Roberto advanced through roles including Head of Analytical Development and Quality Control Manager. Roberto's educational background includes a degree in Ciencias Químicas from Universidad de Alcalá de Henares.
This person is not in any teams
This person is not in any offices
Insud Pharma
5 followers
INSUD PHARMA operates across the entire pharmaceutical value chain, delivering specialized expertise and experience in scientific research, development, manufacturing, sales and marketing of a wide range of value-adding active pharmaceutical ingredients (APIs), finished dosage forms (FDFs) and branded pharmaceuticals, for human and animal health. While the main offices are located in Madrid, Lugano, Buenos Aires, INSUD PHARMA is acting worldwide, creating a broad and balanced manufacturing and commercial network across Europe, America, Asia and Africa, to address global opportunities and customers` needs in all major pharmaceutical markets. INSUD PHARMA's activity is organized in three synergistic business areas: Industrial (Chemo), Branded (Exeltis) and Biotech (mAbxience), with over 7,300 professionals in more than 50 countries, 18 state-of-the-art facilities, 15 specialized R&D centers, 12 commercial offices and more than 35 pharmaceutical affiliates, serving 1,150 customers in 96 countries around the world. INSUD PHARMA believes in innovation and sustainable development. Our commitment is to improve people`s health and quality of life, providing access to quality medicines at affordable prices, and to continuously expand our efforts and R&D investment to develop new and better therapies.